Outlook for FY 23
The company is lowering its revenue guidance to Rs 300 cr while it expects the EBITDA margins
will increase to be in the range of 24% to 26%. It expects its R&D driven complex injectable
portfolio, new partnerships & product registrations and expansion into new geographies will
drive growth in the coming years.
439f8efd-313e-4d92-a006-0e0a2dbc6551.pdf (5.6 MB)
| Subscribe To Our Free Newsletter |
